Margareta Puu

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction

Lars Olsson, Karl Swedberg, Anique Ducharme et al. · Journal of the American College of Cardiology · 2006 · 572 citations

Medicine, Cardiology, Clinical Cardiology +14

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Anique Ducharme, Karl Swedberg, Marc A. Pfeffer et al. · American Heart Journal · 2006 · 355 citations

Medicine, Cardiology, Pharmacology +16

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

Paul M. O’Byrne, Hristo Metev, Margareta Puu et al. · The Lancet Respiratory Medicine · 2016 · 260 citations

Pharmacy, Pharmacology, Pharmacotherapy +9

A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis

Anthony De Soyza, Ian Pavord, J.S. Elborn et al. · European Respiratory Journal · 2015 · 108 citations

Veterinary Medicine, Pharmacology, Pharmacotherapy +11

Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study

Paul M. O’Byrne, J. Mark FitzGerald, Eric D. Bateman et al. · The Lancet Respiratory Medicine · 2020 · 75 citations

Pharmacy, Pharmacology, Pharmacotherapy +16